Conversation 167: Paincheck CEO says business on track to hit $6 to $7 million in recurring revenue.

Written By Phil Carey

In his latest CEO Conversation, Philip Daffas of PainChek [ASX:PCK] told Phil Carey that “The share price clearly under represents our achievements as we are no longer a speculative company”.

Daffas believes the share price is lagging behind the achievements of the company.

PainChek has a phone based app that quickly and accurately measures the level of pain a person is in. This is particularly useful and aged care and for young children.

“A bit like my experience at Cochlear, the more we deliver, the more the share price will evolve” he said.

In Conversation 167, we cover how COVID has led to a complete overhaul of how PainChek markets, sells and handles installation and training of the app, along with the current status of its collaboration with Phillips Health and the progress of the childrens app version of PainChek.

Phil Carey https://www.cornerstonemedia.com.au
Previous

Conversation 169: Does IMEXHS have what it takes to grab new markets by the throat?
Next

Conversation 166: Intuitive Surgical robots carry out procedures every 26 seconds.